JP2003533488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003533488A5 JP2003533488A5 JP2001583797A JP2001583797A JP2003533488A5 JP 2003533488 A5 JP2003533488 A5 JP 2003533488A5 JP 2001583797 A JP2001583797 A JP 2001583797A JP 2001583797 A JP2001583797 A JP 2001583797A JP 2003533488 A5 JP2003533488 A5 JP 2003533488A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- polypeptide
- composition according
- agent
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 15
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 15
- 102000003812 Interleukin-15 Human genes 0.000 description 13
- 108090000172 Interleukin-15 Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000056003 human IL15 Human genes 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20380100P | 2000-05-12 | 2000-05-12 | |
| US60/203,801 | 2000-05-12 | ||
| PCT/US2001/015578 WO2001087330A2 (en) | 2000-05-12 | 2001-05-14 | Compositions and methods for achieving immune suppression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003533488A JP2003533488A (ja) | 2003-11-11 |
| JP2003533488A5 true JP2003533488A5 (enExample) | 2008-07-03 |
Family
ID=22755375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001583797A Pending JP2003533488A (ja) | 2000-05-12 | 2001-05-14 | 免疫抑制を達成するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6797263B2 (enExample) |
| EP (1) | EP1284747A2 (enExample) |
| JP (1) | JP2003533488A (enExample) |
| CN (1) | CN1441675A (enExample) |
| AU (2) | AU6158501A (enExample) |
| BR (1) | BR0110779A (enExample) |
| CA (1) | CA2408691A1 (enExample) |
| RU (1) | RU2270691C2 (enExample) |
| WO (1) | WO2001087330A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| WO2004035787A2 (de) * | 2002-10-14 | 2004-04-29 | F. Hoffmann-La Roche Ag | Transplantierbare zelle mit immunmodulator |
| US7892745B2 (en) | 2003-04-24 | 2011-02-22 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
| EP1756155A2 (en) * | 2004-04-14 | 2007-02-28 | F.Hoffmann-La Roche Ag | PURIFIED INTERLEUKIN-15/Fc FUSION PROTEIN AND PREPARATION THEREOF |
| US7645575B2 (en) * | 2004-09-08 | 2010-01-12 | Xdx, Inc. | Genes useful for diagnosing and monitoring inflammation related disorders |
| JP2008539765A (ja) * | 2005-05-13 | 2008-11-20 | ユニバーシティー オブ マイアミ | 移植片拒絶反応および自己免疫疾患における、同種異系抗原または自己抗原に対する細胞応答の分子精査 |
| PL1901773T3 (pl) * | 2005-06-09 | 2012-09-28 | Hansa Medical Ab | Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu |
| JP5709356B2 (ja) | 2006-01-13 | 2015-04-30 | アメリカ合衆国 | 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子 |
| WO2008021431A2 (en) | 2006-08-14 | 2008-02-21 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders |
| EP2102367A2 (en) | 2006-11-09 | 2009-09-23 | XDX, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
| CA2690825C (en) * | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| NZ714757A (en) | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| CN105017429B (zh) | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| SI2665486T1 (sl) | 2011-01-18 | 2020-07-31 | Bioniz, Llc | Sestavki za moduliranje aktivnosti gama-C-citokina |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| EP3160498B1 (en) | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| WO2018075989A1 (en) | 2016-10-21 | 2018-04-26 | Altor Bioscience Corporation | Multimeric il-15-based molecules |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| EP3630843A2 (en) | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| CN107474143B (zh) * | 2017-09-13 | 2020-08-11 | 深圳市因诺赛生物科技有限公司 | (Anti-CD40 mAb)-CTLA4融合蛋白及其用途 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| WO2020227019A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| EP4619421A2 (en) * | 2023-05-01 | 2025-09-24 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Mutant interleukin 15 expressing immune cells |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| CA2121798C (en) | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
| GB9207732D0 (en) | 1992-04-06 | 1992-05-27 | Isis Innovation | Wound repair |
| KR0170037B1 (ko) | 1992-08-20 | 1999-02-01 | 에릭 에스. 딕커 | 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물 |
| WO1994004570A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| JPH08510719A (ja) | 1993-02-01 | 1996-11-12 | ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル | 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用 |
| US5747024A (en) | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| EP0721346B1 (en) | 1993-09-02 | 1998-06-10 | Trustees of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
| CN1137726C (zh) | 1993-09-02 | 2004-02-11 | 达特茅斯学院理事 | 延长体液免疫抑制的方法 |
| CA2186747C (en) | 1994-04-06 | 2009-01-27 | Kenneth H. Grabstein | Interleukin-15 |
| US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| US6265556B1 (en) | 1994-12-02 | 2001-07-24 | The Burnham Institute | Nucleic acid encoding CD40 associated proteins |
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US5833987A (en) | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| US6132978A (en) | 1995-12-19 | 2000-10-17 | National Jewish Medical And Research Center | Method to regulate CD40 signaling |
| JP2000503659A (ja) | 1996-01-16 | 2000-03-28 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティー オブ ニューヨーク | 自己抗体の沈着以外の開始点を有する炎症性腎疾患を処置するためのｔ―ｂａｍ（ｃｄ４０―ｌ）技術の治療的適用 |
| JP4751493B2 (ja) | 1996-03-20 | 2011-08-17 | ブリストル−マイヤーズ スクイッブ カンパニー | Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物 |
| CA2252557A1 (en) * | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of interleukin-15 |
| IL127884A0 (en) | 1996-07-08 | 1999-10-28 | Univ Columbia | Agents for inhibiting activation of cells bearing C40 on the cell surface selection and use thereof |
| DE19823351A1 (de) | 1997-05-16 | 1998-12-10 | Krause Hans | Mittel zur Verhinderung der Zellapoptose bei Krankheiten |
| HUP0003392A3 (en) | 1997-05-17 | 2002-09-30 | Biogen Idec Ma Inc Cambridge | Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
| AU748533B2 (en) | 1997-06-11 | 2002-06-06 | United States Of America As Represented By The Secretary Of The Navy, The | Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses |
| IL133305A0 (en) | 1997-06-20 | 2001-04-30 | Biogen Inc | Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome |
| AU8266798A (en) | 1997-06-27 | 1999-01-19 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
-
2001
- 2001-05-14 JP JP2001583797A patent/JP2003533488A/ja active Pending
- 2001-05-14 WO PCT/US2001/015578 patent/WO2001087330A2/en not_active Ceased
- 2001-05-14 CA CA002408691A patent/CA2408691A1/en not_active Abandoned
- 2001-05-14 EP EP01935495A patent/EP1284747A2/en not_active Withdrawn
- 2001-05-14 AU AU6158501A patent/AU6158501A/xx active Pending
- 2001-05-14 AU AU2001261585A patent/AU2001261585B2/en not_active Ceased
- 2001-05-14 RU RU2002133447/15A patent/RU2270691C2/ru not_active IP Right Cessation
- 2001-05-14 BR BR0110779-8A patent/BR0110779A/pt not_active IP Right Cessation
- 2001-05-14 CN CN01812646A patent/CN1441675A/zh active Pending
- 2001-05-14 US US09/855,313 patent/US6797263B2/en not_active Expired - Fee Related
-
2004
- 2004-05-25 US US10/853,466 patent/US7347995B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003533488A5 (enExample) | ||
| US7875709B2 (en) | Nucleic acids encoding interleukin-18 mutants | |
| ES2383328T3 (es) | Métodos relacionados con LDCAM y CRTAM | |
| JP2004525076A5 (enExample) | ||
| CN1317301C (zh) | Il－2－和il－15－介导的t细胞应答的调节 | |
| EP1102848B1 (en) | Molecules designated ldcam | |
| US20020165156A1 (en) | BAFF receptor (BCMA), an immunoregulatory agent | |
| JP2007267750A (ja) | 可溶性ｉｌ−ｔｉｆ／ｉｌ−２２レセプターまたはｉｌ−ｔｉｆ／ｉｌ−２２に結合する結合タンパク質をコードする単離された核酸分子、およびその使用 | |
| HU216310B (hu) | Eljárás citokinszintézis inhibitorfaktor (CSIF), CSIF-aktivitású polipeptidek és CSIF-antagonisták, valamint ezeket tartalmazó gyógyszerkészítmények előállítására | |
| KR20060052681A (ko) | Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도 | |
| JPH07508179A (ja) | ヒトインターロイキン−１３ | |
| JP2003533488A (ja) | 免疫抑制を達成するための組成物および方法 | |
| AU2002324249A1 (en) | Interleukin-18 mutants, their production and use | |
| JP2005516606A (ja) | 哺乳動物のサイトカイン；関連する試薬の使用 | |
| JPH10511266A (ja) | ヒト・インターロイキン−１１受容体 | |
| US7189400B2 (en) | Methods of treatment with antagonists of MU-1 | |
| Shilovskiy et al. | Role and molecular mechanisms of alternative splicing of Th2-cytokines IL-4 and IL-5 in atopic bronchial asthma | |
| JP2010183921A (ja) | ＩＬ−１ゼータ、ＩＬ−１ゼータスプライス変異体およびＸｒｅｃ２のＤＮＡおよびポリペプチド | |
| JP4623342B2 (ja) | Ｉｌ−１エータのｄｎａ及びポリペプチド | |
| JP5642769B2 (ja) | 慢性閉塞性肺疾患及び喘息を治療するための組成物及び方法 | |
| JP2000508909A (ja) | 分泌蛋白およびそれらをコードしているポリヌクレオチド | |
| JP2000515726A (ja) | 分泌蛋白をコードする成人ｐｂｍｃ由来のポリヌクレオチド | |
| EP1104771A1 (en) | NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF | |
| EP1022336A1 (en) | POLYPEPTIDE, cDNA ENCODING THE SAME, AND USE OF THEM | |
| JP2000508908A (ja) | 分泌蛋白およびそれらをコードしているポリヌクレオチド |